Bausch Health Companies Inc. (TSE:BHC - Free Report) - Equities researchers at Zacks Research increased their FY2024 earnings per share (EPS) estimates for shares of Bausch Health Companies in a note issued to investors on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $5.21 per share for the year, up from their previous estimate of $4.98. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q4 2024 earnings at $1.57 EPS, Q1 2025 earnings at $1.19 EPS, Q2 2025 earnings at $1.40 EPS, Q3 2025 earnings at $1.57 EPS, Q4 2025 earnings at $1.79 EPS, FY2025 earnings at $5.96 EPS, Q1 2026 earnings at $1.51 EPS, Q2 2026 earnings at $1.57 EPS, Q3 2026 earnings at $1.90 EPS and FY2026 earnings at $7.01 EPS.
Separately, Evercore ISI upgraded Bausch Health Companies to a "hold" rating in a report on Tuesday, October 15th.
View Our Latest Analysis on Bausch Health Companies
Bausch Health Companies Trading Down 1.1 %
Shares of BHC stock traded down C$0.13 on Friday, hitting C$11.32. The stock had a trading volume of 87,255 shares, compared to its average volume of 369,248. The company has a debt-to-equity ratio of 7,583.76, a current ratio of 1.19 and a quick ratio of 0.58. The firm has a market capitalization of C$4.16 billion, a P/E ratio of -6.54, a P/E/G ratio of 0.21 and a beta of 0.77. Bausch Health Companies has a 1 year low of C$5.45 and a 1 year high of C$15.43. The company's 50 day moving average price is C$11.28 and its 200-day moving average price is C$9.86.
Bausch Health Companies (TSE:BHC - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported C$1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of C$1.43 by C$0.10. The firm had revenue of C$3.42 billion for the quarter, compared to the consensus estimate of C$3.36 billion. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%.
Insiders Place Their Bets
In other Bausch Health Companies news, Senior Officer Seana Lynne Carson sold 13,370 shares of the company's stock in a transaction dated Friday, September 6th. The stock was sold at an average price of C$8.38, for a total transaction of C$112,087.40. 11.28% of the stock is owned by company insiders.
About Bausch Health Companies
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
Further Reading
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
